Lateral Flow Assay (LFA) has been adapted for the detection of Cryptococcus, offering a rapid and convenient method for diagnosis. The LFA for Cryptococcus utilizes capture antibodies that specifically target Cryptococcus antigens, such as capsular polysaccharides like glucuronoxylomannan. These antibodies are immobilized on the test line of the nitrocellulose membrane. During the assay, when a patient sample, such as serum or cerebrospinal fluid, is applied to the LFA, Cryptococcus antigens present in the sample interact with the capture antibodies on the test line. Colored nanoparticles conjugated with secondary antibodies then bind to the captured antigens, resulting in the appearance of a visible line. The presence of this line indicates a positive result for Cryptococcus infection, facilitating rapid diagnosis and appropriate patient management.

 

In mycology, the most widely used LFA test is the Cryptococcus Antigen Detection Test.

 

The IMMY CrAg LFA (Cryptococcal Antigen Lateral Flow Assay) is an immunochromatographic dipstick assay for the qualitative and semiquanitative detection of cryptococcal antigen. This lateral flow assay is revolutionizing cryptococcal antigen testing, by delivering analytical sensitivity that is up to 200x more sensitive than other commercial assays. The CrAg LFA is empowering health care providers in all clinical settings with rapid, reliable, and robust diagnostic results.